Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 993Neoplasms 852Carcinoma, Non-Small-Cell Lung 844Prostatic Neoplasms 528Neoplasm Metastasis 501Leukemia, Myeloid, Acute 489Melanoma 456Colorectal Neoplasms 447Multiple Myeloma 441Lung Neoplasms 421Pancreatic Neoplasms 353Recurrence 350Lymphoma 350Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 329Leukemia 324Leukemia, Lymphocytic, Chronic, B-Cell 302Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 245Carcinoma, Hepatocellular 234Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Myelodysplastic Syndromes 230Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

aprutumab ixadotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × Medical Oncology × Clear all
NCT02368951 2017-07-12

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Bayer

Phase 1 Terminated
20 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡